Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/16/2019 05/17/2019 05/20/2019 05/21/2019 05/22/2019 Date
63.46(c) 61.43(c) 58.54(c) 59.5(c) 58.57(c) Last
354 412 455 892 519 293 411 714 221 434 Volume
+0.95% -3.20% -4.70% +1.64% -1.56% Change
More quotes
Financials (USD)
Sales 2019 97,3 M
EBIT 2019 -387 M
Net income 2019 -377 M
Finance 2019 355 M
Yield 2019 -
Sales 2020 211 M
EBIT 2020 -284 M
Net income 2020 -281 M
Finance 2020 354 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 31,5x
EV / Sales2020 14,5x
Capitalization 3 420 M
More Financials
Company
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics... 
Sector
Biotechnology & Medical Research
Calendar
06/11 | 05:00pmShareholder meeting
More about the company
Surperformance© ratings of Ultragenyx Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on ULTRAGENYX PHARMACEUTICAL
05/10ULTRAGENYX PHARMACEUTICAL : to Present at Bank of America Merrill Lynch Healthca..
AQ
05/07ULTRAGENYX PHARMACEUTICAL : Management's Discussion and Analysis of Financial Co..
AQ
05/06ULTRAGENYX PHARMACEUTICAL INC. : Results of Operations and Financial Condition, ..
AQ
05/06ULTRAGENYX : 1Q Earnings Snapshot
AQ
05/06Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
GL
05/03ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement (for..
AQ
04/30Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results a..
GL
04/17ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure (form 8-K)
AQ
04/16ULTRAGENYX PHARMACEUTICAL : Announces UX007 Granted Fast Track Designation and R..
AQ
04/11Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 1..
GL
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL
More recommendations
Sector news : Bio Therapeutic Drugs
05/21Global chemical firms urged to source responsibly after lethal China blast - ..
RE
05/15GILEAD SCIENCES : Novartis gets approval to sell Kymriah in Japan for $306,000
RE
05/13REGENERON PHARMACEUTICALS : Says FDA Approves Eylea Injection for All Diabetic R..
DJ
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
05/09PATRICK THOMAS : Biotech Is Place to Be for Top Salaries
DJ
More sector news : Bio Therapeutic Drugs
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 75,5 $
Spread / Average Target 27%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC36.84%3 364
GILEAD SCIENCES6.31%83 745
VERTEX PHARMACEUTICALS2.06%42 447
REGENERON PHARMACEUTICALS-14.30%32 595
GENMAB12.27%10 632
SAREPTA THERAPEUTICS INC11.45%8 718